Printer Friendly

Eli Lilly Japan Obtains Additional Approval for Gemzar Injection.

Tokyo, Japan, July 11, 2006 - (JCN) - Eli Lilly Japan announced o June 4 that it has obtained additional approval for Gemzar Injection (gemcitabine HC1), its proprietary anti-cancer agent, from the Ministry of Health, Labor and Welfare.

The agent will now be available for the treatment of biliary tract cancer.

Initially approved in Japan in March 1999, Gemzar is currently indicated for the treatments of non-small cell lung cancer and pancreatic cancer.

The company expects that Gemzar, with its superior response rate and reduced side effects, will be an optimal choice for patients with biliary tract cancer.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Geographic Code:9JAPA
Date:Jul 12, 2006
Previous Article:Hitachi High-Technologies Launches Mask Design Data Measuring System.
Next Article:Toray Ireeve Releases Ultrasonic Electric Toothbrush.

Related Articles
Kyowa Hakko Kogyo Licenses Anti-tumor Drug Candidate Mitotic Kinesin Eg5 Inhibitor to Eli Lilly.
Human Growth Hormone Agent Humatrope Now Available for Treatment of Adult Growth Hormone Deficiency.
Rights group up against Eli Lilly.
Advocates seek access to drug company documents.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters